Humacyte (HUMA) CEO indirectly awarded 80,000 stock options via spouse

Q: What insider transaction did Humacyte (HUMA) report for Laura E. Niklason?

Humacyte reported an indirect acquisition of 80,000 stock options for common stock by President and CEO Laura E. Niklason through her spouse. These options give the right to buy shares at a fixed exercise price over time.

Q: What is the exercise price of the new Humacyte (HUMA) stock options?

The granted stock options have an exercise price of $1.08 per share . This means the holder can buy Humacyte common stock at $1.08 per share once the options vest and are exercisable, regardless of the market price at that time.

Q: How many Humacyte (HUMA) stock options were granted in this Form 4 filing?

The filing reports a grant of 80,000 stock options linked to Humacyte common stock. All 80,000 options are held indirectly through the CEO’s spouse and represent a compensation-related award, not an open-market purchase or sale of existing shares.

Q: When do the newly granted Humacyte (HUMA) options start vesting?

The vesting begins on June 11, 2027 , when the first 25% of the options become exercisable. After that date, 1/48 of the options vest monthly on the 11th of each month until June 11, 2030, completing the vesting schedule.

Q: What is the expiration date of the Humacyte (HUMA) stock options granted?

The stock options granted in this transaction expire on June 11, 2036 . After this expiration date, any unexercised options become worthless, so the holder must exercise vested options before that date to acquire common shares.

Q: Are the Humacyte (HUMA) options held directly by the CEO or indirectly?

The options are reported as held indirectly "By spouse" . This means the economic interest is attributed to an immediate family member, and the Form 4 shows the CEO’s indirect beneficial ownership of these 80,000 stock options.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Humacyte, Inc. reported that President and CEO Laura E. Niklason had an indirect acquisition of stock options through her spouse. The grant covers 80,000 stock options for Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036. According to the vesting schedule, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Niklason Laura E

Role President, CEO and Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 80,000 shares (Indirect, By spouse)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 80,000 options Exercise price: $1.08 per share Options expiration: June 11, 2036 +3 more

6 metrics

Stock options granted 80,000 options Grant/award acquisition reported on Form 4

Exercise price $1.08 per share Conversion or exercise price of stock options

Options expiration June 11, 2036 Expiration date of granted stock options

Initial vesting date June 11, 2027 First 25% of options become exercisable

Monthly vesting pattern 1/48 each month Remaining options vest monthly through June 11, 2030

Indirectly held options after transaction 80,000 options Total stock options held indirectly by spouse following transaction

Key Terms

Stock Options (right to buy), indirect, Grant, award, or other acquisition, underlying security, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

indirect financial

"ownership_type: indirect; nature_of_ownership: By spouse"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock; underlying_security_shares"

vest financial

"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 05:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Niklason Laura E

(Last)

(First)

(Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM

NORTH CAROLINA

27713

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, CEO and Director

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		⁽¹⁾	06/11/2036	Common Stock	80,000	$0	80,000	I	By spouse

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Humacyte (HUMA) report for Laura E. Niklason?

Humacyte reported an indirect acquisition of 80,000 stock options for common stock by President and CEO Laura E. Niklason through her spouse. These options give the right to buy shares at a fixed exercise price over time.

What is the exercise price of the new Humacyte (HUMA) stock options?

The granted stock options have an exercise price of $1.08 per share. This means the holder can buy Humacyte common stock at $1.08 per share once the options vest and are exercisable, regardless of the market price at that time.

How many Humacyte (HUMA) stock options were granted in this Form 4 filing?

The filing reports a grant of 80,000 stock options linked to Humacyte common stock. All 80,000 options are held indirectly through the CEO’s spouse and represent a compensation-related award, not an open-market purchase or sale of existing shares.

When do the newly granted Humacyte (HUMA) options start vesting?

The vesting begins on June 11, 2027, when the first 25% of the options become exercisable. After that date, 1/48 of the options vest monthly on the 11th of each month until June 11, 2030, completing the vesting schedule.

What is the expiration date of the Humacyte (HUMA) stock options granted?

The stock options granted in this transaction expire on June 11, 2036. After this expiration date, any unexercised options become worthless, so the holder must exercise vested options before that date to acquire common shares.

Are the Humacyte (HUMA) options held directly by the CEO or indirectly?

The options are reported as held indirectly "By spouse". This means the economic interest is attributed to an immediate family member, and the Form 4 shows the CEO’s indirect beneficial ownership of these 80,000 stock options.